Álvaro Hernáez1, Alan T Remaley2, Marta Farràs3, Sara Fernández-Castillejo4, Isaac Subirana5, Helmut Schröder6, Mireia Fernández-Mampel7, Daniel Muñoz-Aguayo8, Maureen Sampson2, Rosa Solà9, Magí Farré10, Rafael de la Torre11, María-Carmen López-Sabater12, Kristiina Nyyssönen13, Hans-Joachim F Zunft14, María-Isabel Covas8, Montserrat Fitó15. 1. Cardiovascular Risk and Nutrition Research Group, REGICOR Study Group, CIBER de Fisiopatología de la Nutrición y la Obesidad (CIBEROBN), Spain; PhD Program in Food Sciences and Nutrition and. 2. Lipoprotein Metabolism Section, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD; 3. Cardiovascular Risk and Nutrition Research Group, REGICOR Study Group, CIBER de Fisiopatología de la Nutrición y la Obesidad (CIBEROBN), Spain; PhD Program in Biochemistry, Molecular Biology, and Biomedicine, Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona (UAB), Barcelona, Spain; 4. Research Unit on Lipids and Atherosclerosis, Hospital Universitari Sant Joan, IISPV, Universitat Rovira i Virgili and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Reus, Spain; 5. Cardiovascular Epidemiology and Genetics Research Group, REGICOR Study Group, and CIBER de Epidemiología y Salud Pública (CIBERESP), Spain; 6. Cardiovascular Risk and Nutrition Research Group, REGICOR Study Group, CIBER de Epidemiología y Salud Pública (CIBERESP), Spain; 7. Cardiovascular Risk and Nutrition Research Group, REGICOR Study Group. 8. Cardiovascular Risk and Nutrition Research Group, REGICOR Study Group, CIBER de Fisiopatología de la Nutrición y la Obesidad (CIBEROBN), Spain; 9. CIBER de Fisiopatología de la Nutrición y la Obesidad (CIBEROBN), Spain; 10. Human Pharmacology and Clinical Neurosciences Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Autonomous University of Barcelona (UAB), Cerdanyola del Vallès, Barcelona, Spain; 11. Human Pharmacology and Clinical Neurosciences Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Department of Experimental and Health Sciences, Pompeu Fabra University (UPF) (CEXS-UPF), Barcelona, Spain; 12. Nutrition and Bromatology Department, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; 13. Institute of Public Health and Clinical Nutrition and Department of Clinical Chemistry, University of Eastern Finland, and Eastern Finland Laboratory Center, Kuopio, Finland; and. 14. German Institute of Human Nutrition (DIFE), Potsdam-Rehbruecke, Germany. 15. Cardiovascular Risk and Nutrition Research Group, REGICOR Study Group, CIBER de Fisiopatología de la Nutrición y la Obesidad (CIBEROBN), Spain; mfito@imim.es.
Abstract
BACKGROUND:Olive oil polyphenols have shown protective effects on cardiovascular risk factors. Their consumption decreased oxidative stress biomarkers and improved some features of the lipid profile. However, their effects on LDL concentrations in plasma and LDL atherogenicity have not yet been elucidated. OBJECTIVE: Our objective was to assess whether the consumption of olive oil polyphenols could decrease LDL concentrations [measured as apolipoprotein B-100 (apo B-100) concentrations and the total number of LDL particles] and atherogenicity (the number of small LDL particles and LDL oxidizability) in humans. METHODS: The study was a randomized, cross-over controlled trial in 25 healthy European men, aged 20-59 y, in the context of the EUROLIVE (Effect of Olive Oil Consumption on Oxidative Damage in European Populations) study. Volunteers ingested 25 mL/d raw low-polyphenol-content olive oil (LPCOO; 366 mg/kg) or high-polyphenol-content olive oil (HPCOO; 2.7 mg/kg) for 3 wk. Interventions were preceded by 2-wk washout periods. Effects of olive oil polyphenols on plasma LDL concentrations and atherogenicity were determined in the sample of 25 men. Effects on lipoprotein lipase (LPL) gene expression were assessed in another sample of 18 men from the EUROLIVE study. RESULTS:Plasma apoB-100 concentrations and the number of total and small LDL particles decreased (mean ± SD: by 5.94% ± 16.6%, 11.9% ± 12.0%, and 15.3% ± 35.1%, respectively) from baseline after the HPCOO intervention. These changes differed significantly from those after the LPCOO intervention, which resulted in significant increases of 6.39% ± 16.6%, 4.73% ± 22.0%, and 13.6% ± 36.4% from baseline (P < 0.03). LDL oxidation lag time increased by 5.0% ± 10.3% from baseline after the HPCOO intervention, which was significantly different only relative to preintervention values (P = 0.038). LPL gene expression tended to increase by 26% from baseline after the HPCOO intervention (P = 0.08) and did not change after the LPCOO intervention. CONCLUSION: The consumption of olive oil polyphenols decreased plasma LDL concentrations and LDL atherogenicity in healthy young men. This trial was registered at www.controlled-trials.com as ISRCTN09220811.
RCT Entities:
BACKGROUND:Olive oil polyphenols have shown protective effects on cardiovascular risk factors. Their consumption decreased oxidative stress biomarkers and improved some features of the lipid profile. However, their effects on LDL concentrations in plasma and LDL atherogenicity have not yet been elucidated. OBJECTIVE: Our objective was to assess whether the consumption of olive oil polyphenols could decrease LDL concentrations [measured as apolipoprotein B-100 (apo B-100) concentrations and the total number of LDL particles] and atherogenicity (the number of small LDL particles and LDL oxidizability) in humans. METHODS: The study was a randomized, cross-over controlled trial in 25 healthy European men, aged 20-59 y, in the context of the EUROLIVE (Effect of Olive Oil Consumption on Oxidative Damage in European Populations) study. Volunteers ingested 25 mL/d raw low-polyphenol-content olive oil (LPCOO; 366 mg/kg) or high-polyphenol-content olive oil (HPCOO; 2.7 mg/kg) for 3 wk. Interventions were preceded by 2-wk washout periods. Effects of olive oil polyphenols on plasma LDL concentrations and atherogenicity were determined in the sample of 25 men. Effects on lipoprotein lipase (LPL) gene expression were assessed in another sample of 18 men from the EUROLIVE study. RESULTS: Plasma apo B-100 concentrations and the number of total and small LDL particles decreased (mean ± SD: by 5.94% ± 16.6%, 11.9% ± 12.0%, and 15.3% ± 35.1%, respectively) from baseline after the HPCOO intervention. These changes differed significantly from those after the LPCOO intervention, which resulted in significant increases of 6.39% ± 16.6%, 4.73% ± 22.0%, and 13.6% ± 36.4% from baseline (P < 0.03). LDL oxidation lag time increased by 5.0% ± 10.3% from baseline after the HPCOO intervention, which was significantly different only relative to preintervention values (P = 0.038). LPL gene expression tended to increase by 26% from baseline after the HPCOO intervention (P = 0.08) and did not change after the LPCOO intervention. CONCLUSION: The consumption of olive oil polyphenols decreased plasma LDL concentrations and LDL atherogenicity in healthy young men. This trial was registered at www.controlled-trials.com as ISRCTN09220811.
Authors: E Gimeno; M Fitó; R M Lamuela-Raventós; A I Castellote; M Covas; M Farré; M C de La Torre-Boronat; M C López-Sabater Journal: Eur J Clin Nutr Date: 2002-02 Impact factor: 4.016
Authors: Brenda M Davy; Kevin P Davy; Richard C Ho; Stacy D Beske; Linda R Davrath; Christopher L Melby Journal: Am J Clin Nutr Date: 2002-08 Impact factor: 7.045
Authors: Audrey Hendrickson; Laura A McKinstry; Julieann K Lewis; Jeremy Lum; Andy Louie; Gerard D Schellenberg; Thomas S Hatsukami; Alan Chait; Gail P Jarvik Journal: Atherosclerosis Date: 2004-11-11 Impact factor: 5.162
Authors: Olga Castañer; María-Isabel Covas; Olha Khymenets; Kristiina Nyyssonen; Valentini Konstantinidou; Hans-Franz Zunft; Rafael de la Torre; Daniel Muñoz-Aguayo; Joan Vila; Montserrat Fitó Journal: Am J Clin Nutr Date: 2012-03-21 Impact factor: 7.045
Authors: María-Isabel Covas; Kristiina Nyyssönen; Henrik E Poulsen; Jari Kaikkonen; Hans-Joachim F Zunft; Holger Kiesewetter; Antonio Gaddi; Rafael de la Torre; Jaakko Mursu; Hans Bäumler; Simona Nascetti; Jukka T Salonen; Montserrat Fitó; Jyrki Virtanen; Jaume Marrugat Journal: Ann Intern Med Date: 2006-09-05 Impact factor: 25.391
Authors: Michael Y Tsai; Brian T Steffen; Weihua Guan; Robyn L McClelland; Russell Warnick; Joseph McConnell; Daniel M Hoefner; Alan T Remaley Journal: Arterioscler Thromb Vasc Biol Date: 2013-11-14 Impact factor: 8.311
Authors: Jaume Marrugat; María-Isabel Covas; Montserrat Fitó; Helmut Schröder; Elisabet Miró-Casas; Eva Gimeno; M Carmen López-Sabater; Rafael de la Torre; Magí Farré Journal: Eur J Nutr Date: 2004-01-06 Impact factor: 5.614
Authors: Katerina Sarapis; Elena S George; Wolfgang Marx; Hannah L Mayr; Jane Willcox; Tammy Esmaili; Katie L Powell; Oladayo S Folasire; Anna E Lohning; Manohar Garg; Colleen J Thomas; Catherine Itsiopoulos; George Moschonis Journal: Eur J Nutr Date: 2021-10-30 Impact factor: 5.614
Authors: Sara Fernández-Castillejo; Rosa-Maria Valls; Olga Castañer; Laura Rubió; Úrsula Catalán; Anna Pedret; Alba Macià; Maureen L Sampson; María-Isabel Covas; Montserrat Fitó; Maria-José Motilva; Alan T Remaley; Rosa Solà Journal: Mol Nutr Food Res Date: 2016-05-06 Impact factor: 5.914
Authors: Sara Biel; Maria-Dolores Mesa; Rafael de la Torre; Juan-Antonio Espejo; Jose-Ramón Fernández-Navarro; Montserrat Fitó; Estefanía Sánchez-Rodriguez; Carmen Rosa; Rosa Marchal; Juan de Dios Alche; Manuela Expósito; Manuel Brenes; Beatriz Gandul; Miguel Angel Calleja; María-Isabel Covas Journal: BMC Complement Altern Med Date: 2016-10-22 Impact factor: 3.659
Authors: Kay-Tee Khaw; Stephen J Sharp; Leila Finikarides; Islam Afzal; Marleen Lentjes; Robert Luben; Nita G Forouhi Journal: BMJ Open Date: 2018-03-06 Impact factor: 2.692